RxDoctor Payments Data

Harry Kaplan, MD

Internal Medicine · Baltimore, MDNPI 1538124631

Payments from drug & device makers

$21,655in general payments, 2019–2025

Across 534 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$13K
  • AbbVie$1K
  • Novo Nordisk$918
  • Pfizer$653
  • Johnson & Johnson$568
  • Lilly USA, LLC$553
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$1,6207%
  • Speaking & faculty fees$10,20047%
  • Travel & lodging$1501%
  • Food & beverage$9,61744%
  • Education$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,655 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$176,085
Medicare patients
329
Services billed
1,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$148,898
OzempicSemaglutide68$110,304
Repatha SureclickEvolocumab80$96,546
MounjaroTirzepatide78$76,966
XareltoRivaroxaban61$62,459
JardianceEmpagliflozin28$46,772
FarxigaDapagliflozin Propanediol30$39,552
Teriparatide12$29,338
LinzessLinaclotide29$17,034
Praluent PenAlirocumab11$15,195
MyrbetriqMirabegron22$13,629
Dexlansoprazole DrDexlansoprazole33$9,900
NexlizetBempedoic Acid/Ezetimibe11$9,501
Tresiba Flextouch U-100Insulin Degludec14$7,720
PaxlovidNirmatrelvir/Ritonavir54$7,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$653$156,044172 claims
Novo NordiskOzempic$918$110,30468 claims
Lilly USA, LLCMounjaro$553$76,96678 claims
Johnson & JohnsonXarelto$568$62,45961 claims
Boehringer IngelheimJardiance$54$46,77228 claims
AstraZenecaFarxiga$432$39,55230 claims
Alvogen IncTeriparatide$16$29,33812 claims
AbbVieLinzess, Synthroid$1,301$21,25468 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$150$16,41628 claims
Astellas Pharma US IncMyrbetriq$118$13,62922 claims
Kowa Pharmaceuticals America, Inc.Livalo$241$6,84812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →